Sanofi Share Price

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.  The company provides pharmaceutical products in various therapeutic areas through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. Sanofi India share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

The Sanofi India stock price is influenced by several key factors, including product portfolio performance, new drug approvals, regulatory changes from bodies like the DCGI and NPPA, and the overall competitive intensity in the generics and patented drugs market. Long-term strategies such as research collaborations, expansion into chronic therapies, and supply chain efficiencies also play a crucial role in shaping market sentiment. All these factors must be closely monitored to have an idea about the ABC stock price movements.  

Sanofi India live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Sanofi India live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Sanofi India share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. 

Sanofi India Limited Company Fundamentals 

A. Company Background 

Sanofi is a global biopharmaceutical company focused on developing medicines and vaccines across multiple therapeutic areas. Headquartered in Paris, the company operates in more than 60 countries and its healthcare solutions are available in over 130 countries worldwide. Globally, Sanofi delivers more than 2.1 billion healthcare solutions annually and vaccinates around 500 million people each year through its vaccines portfolio. The company emphasizes research and development, using advanced technologies including artificial intelligence to support drug discovery and healthcare innovation. Sanofi India Limited represents the group’s operations in India and has been present in the country since 1956, when it was incorporated as Hoechst Fedco Pharmaceutical Private Limited. Over time, the company underwent several name changes—including Hoechst India Limited, Hoechst Marion Roussel Limited, and Aventis Pharma Limited—before adopting its current name in 2012. Headquartered in Mumbai, Sanofi India focuses on therapies and healthcare solutions in areas such as diabetes, vaccines, rare diseases, renal and transplant care, and consumer healthcare. The company operates manufacturing and development facilities in India, including a major production site in Goa that supplies medicines for domestic and export markets. With thousands of employees and decades of presence in the country, Sanofi India contributes to pharmaceutical manufacturing, research activities, and distribution of medicines and vaccines across multiple markets. 

B. Company Product Lines 

• Diabetes Care Medicines: Sanofi develops and markets therapies for diabetes management, including insulin-based treatments and oral medications used to regulate blood glucose levels. Key products historically associated with the company include insulin brands and antidiabetic drugs such as Amaryl used for type-2 diabetes management.  

• Vaccines: Through its global vaccines division, the company supplies vaccines for infectious diseases and immunization programs. Sanofi’s vaccine portfolio contributes to the immunization of hundreds of millions of people globally each year.  

• Rare Disease Treatments: The company develops therapies targeting rare and genetic diseases, focusing on specialized treatments that require advanced biotechnology and research capabilities.  

• Renal and Transplant Medicines: Sanofi offers medicines used in transplant medicine and renal care to help prevent organ rejection and manage related health conditions.  

• Cardiology and Central Nervous System Drugs: Its portfolio includes medicines for cardiovascular diseases, hypertension, seizures, and neurological disorders. Examples manufactured at its Goa site include Cardace for cardiovascular conditions and Frisium for seizure disorders.  

• Consumer Healthcare Products: The company also markets widely used over-the-counter medicines and wellness products addressing pain relief, allergy relief, and general health needs. 

C. Company Revenue Model 

• Prescription Pharmaceutical Sales: A major share of revenue is generated through the sale of prescription medicines in therapeutic areas such as diabetes, cardiology, thrombosis, and rare diseases distributed through hospitals, pharmacies, and healthcare providers.  

• Vaccine Distribution: Revenue is generated through global and national vaccine supply programs, including immunization campaigns conducted in collaboration with governments and healthcare institutions.  

• Consumer Healthcare Products: Over-the-counter medicines, wellness products, and health supplements contribute to revenue through retail pharmacy and consumer health distribution networks.  

• Manufacturing and Export Sales: Sanofi operates manufacturing facilities in India, particularly in Goa, producing pharmaceutical formulations for domestic markets and export to developed and developing countries.  

• Research and Development Pipeline: Investment in research enables future revenue generation through new medicines, biologics, and vaccines developed through clinical trials and innovation programs.  

• Strategic Partnerships and Licensing: The company collaborates with research institutions, healthcare organizations, and partners for product development, technology transfer, and commercialization of pharmaceutical innovations. 

D. Geographic Presence 

• Global Operations: Sanofi operates in more than 60 countries, while its medicines and vaccines are distributed in over 130 countries worldwide, supporting a broad international healthcare presence.  

• India Headquarters: Sanofi India Limited is headquartered in Mumbai, Maharashtra, serving as the central hub for corporate operations and management in India.  

• Indian Operational Locations: The company maintains offices and operations in multiple Indian cities including Mumbai, New Delhi, Goa, and Hyderabad, supporting manufacturing, regulatory, and commercial activities.  

• Manufacturing Presence: A major pharmaceutical manufacturing and development facility operates in Goa, producing billions of tablets and capsules annually for domestic use and export markets.  

• Export Markets: Products manufactured in India are supplied to several international markets across developed and developing regions, contributing to Sanofi’s global supply chain 

E. Leadership  

Some of the key leaders of Sanofi India as of March 2026 are: 

• Deepak Arora – Country Lead and Managing Director & General Manager Pharma, India 

• Rachid Ayari – Chief Financial Officer 

• Vinifer Gandhi – India Communications and CSR Lead 

• Bratin Bag – Senior Director, Ethics & Business Integrity (South Asia) 

• Dr. Arvind Gadekar – Southeast Asia & India Established Products Medical Lead 

• Nitya Padmanabhan – Head of India, Vaccines 

• Sudipta Chakraborty – Head of Legal, India 

• Aniket Raje – Regulatory Country Head, India 

• Richa Bakshi – Head of People Excellence, India 

• Mahadev Gawade – Site Head, Manufacturing & Supply, Goa 

• Haresh Vala – Associate Member, Institute of Company Secretaries of India 

F. Key Milestones 

• 1956: Company incorporated in India as Hoechst Fedco Pharmaceutical Private Limited.  

• 1959–1996: Company underwent several name changes including Hoechst Pharmaceuticals, Hoechst India Limited, and Hoechst Marion Roussel Limited.  

• 2001: Aventis Pharma Limited became the listed entity representing the group in India.  

• 2007: Global Development Centre established in Goa to support pharmaceutical formulation and development in the Asia-Pacific region.  

• 2011: Global parent company renamed from Sanofi-Aventis to Sanofi.  

• 2012: Aventis Pharma Limited officially renamed Sanofi India Limited.  

• 2019: Sale of Ankleshwar manufacturing facility as part of strategic restructuring and focus on branded products. 

G. Industry Perspective 

Sanofi India operates in the pharmaceutical and biotechnology industry, which is one of the fastest-growing healthcare sectors globally and a major contributor to India’s healthcare ecosystem. India is currently the third-largest pharmaceutical producer globally by volume and among the top fourteen by value, supported by strong manufacturing capabilities and a large generic medicines industry.  

The Indian pharmaceutical market was valued at approximately USD 66.6 billion in 2025 and is projected to reach USD 88.9 billion by 2030, growing at a compound annual growth rate (CAGR) of about 5.9%. Other industry projections estimate the broader market could expand to USD 120–130 billion by 2030, driven by rising healthcare demand, government initiatives, and pharmaceutical exports.  

India also plays a major role in global medicine supply. The country supplies over 40% of generic medicines in the United States, around 25% of medicines in the United Kingdom, and nearly 60% of global vaccine demand. Within the domestic market, generic prescription drugs account for roughly 69% of pharmaceutical sales, while tablets and capsules dominate formulations with around 56% market share.  

Future growth of the industry is expected to be driven by increasing prevalence of chronic diseases, expansion of health insurance coverage, government production-linked incentive (PLI) schemes for drug manufacturing, and technological advancements such as AI-enabled drug discovery and biotechnology research. 

Sanofi India Stock Market Presence: Listings & Index Representation 

Sanofi India Limited is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange). The company’s shares have been trading on these premier Indian exchanges for decades, providing a robust platform for price discovery and liquidity. The NSE symbol for the company is SANOFI, and its BSE scrip code is 500674. 

Sanofi India is a constituent of several key market indices, reflecting its standing in the pharmaceutical and healthcare space. Its index representation includes the S&P BSE Healthcare, BSE 1000, S&P BSE 250 SmallCap Index, Nifty Microcap 250 Index, Nifty Total Market, S&P BSE MidSmallCap, S&P BSE SmallCap Select Index, S&P BSE SmallCap, and the S&P BSE AllCap. This widespread index presence underscores the company’s relevance within the Indian healthcare sector. 

The inclusion of Sanofi India in these major indices highlights its market capitalisation, compliance standards, and operational scale in the pharmaceutical industry. Listing on the NSE and BSE ensures high liquidity for the stock, while its presence in these indices drives passive institutional fund flows and makes it a key benchmark for tracking performance in the Indian healthcare and small-cap segments. 

Sanofi India Stock Performance and Sanofi India Share Price History 

The Sanofi India share price on NSE and BSE reflects its position as a prominent healthcare company. Performance is driven by product demand, regulatory outcomes, pricing power, and the company’s ability to innovate and maintain its portfolio of established brands. Investors often compare the Sanofi India stock price today with the performance of the Nifty Pharma index and its peers to evaluate relative strength. These underlying drivers become visible through the company’s real-time market movements. Earnings announcements, updates on key product approvals, or changes in drug pricing policies often lead to sharp movements in the Sanofi India share price. Broader sector trends, such as increased focus on healthcare or policy shifts, have also historically influenced the stock. Corporate actions like dividend announcements or rights issues can also lead to short-term fluctuations in the Sanofi India stock price, even when the company’s long-term fundamentals remain intact. This highlights how even in a regulated sector like pharmaceuticals, such events can create temporary volatility. 

While daily moves reflect immediate news flow, longer-term trends are better understood by looking at the Sanofi India share price 52-week high and low. The 52-week high of ₹10,524.95, reached in mid-2024, indicates a period of strong investor confidence driven by robust earnings and a favourable outlook for the company’s chronic therapies. Conversely, the 52-week low of ₹3,415 touched in March 2026 reflects broader market corrections and sector-specific pressures, such as pricing challenges and competitive intensity. These levels capture the impact of patent expiries, new product launches, and overall market sentiment, providing crucial context for the stock’s historical performance. 

The Sanofi India share price history shows a pattern of long-term wealth creation interspersed with periods of volatility. The early 2000s, particularly 2003 and 2004, saw phenomenal growth of 148.86% and 91.29% respectively, driven by a booming economy and a strong bull run in the markets. The Sanofi India stock price was not immune to the global financial crisis, with a sharp correction of -12.11% in 2008, followed by a spectacular recovery of 83.21% in 2009. The period between 2013 and 2018 saw several high-return years, with gains of 22.79% in 2013, 27.05% in 2014, and a remarkable 37.44% in 2018, reflecting sustained earnings growth and the company’s leadership in the Indian pharma market. More recently, the Sanofi India share price has faced significant headwinds, with declines of -23.16% in 2024, -31.64% in 2025, and a further -14.56% in 2026 as of mid-March. 

The Sanofi India stock price has closely followed economic cycles and sector-specific events. For instance, a steep decline in the Sanofi India share price in recent years, including a 38.47% drop over one year and a 58.55% drop over five years, reflects a period of intense competition, pricing pressures in the domestic market, and a broader shift in investor preference towards other sectors. Despite the COVID-19 pandemic creating a surge in demand for healthcare, Sanofi India’s stock remained relatively resilient in 2020 with a 20.27% gain, though it underperformed the broader sector, which saw returns of 153.56% over five years compared to the stock’s negative returns. This divergence highlights how specific company-level factors, such as portfolio concentration and market dynamics, played a larger role than the general sector tailwind.  

The all-time high for the Sanofi India share price was recorded at ₹10,524.95 in June 2024, a level that now seems distant given the subsequent correction. Over a ten-year period, the stock has delivered a negative return of -22.3%, a stark contrast to the 286.47% return generated by its sector. This underperformance has been a key reason for the Sanofi India share price decline, as the market has re-rated the stock based on its growth visibility and competitive positioning compared to its faster-growing peers. 

Sanofi India Investor Relevance and Role in Portfolio 

Sanofi India represents a specific type of holding in a portfolio, offering exposure to the domestic pharmaceutical and consumer healthcare market. Its inclusion in indices like the S&P BSE Healthcare underscores its importance in the sector. For investors, it offers a blend of a strong parentage (Sanofi SA), a stable of trusted brands, and a presence in both acute and chronic therapy areas. The Sanofi India share price is often seen as a proxy for the performance of multinational pharmaceutical companies operating in India. 

Sanofi India’s equity is held by a mix of the parent company and leading domestic and international institutional investors. Top institutional stakeholders include Sanofi, Life Insurance Corporation of India, Nippon Life India Asset Management Limited, Aditya Birla Sun Life AMC Limited, GIC Asset Management Company Ltd., SBI Funds Management Limited, The Vanguard Group, Inc., HDFC Life Insurance Company Limited, Bajaj Life Insurance Limited, and BlackRock, Inc. 

Prominent mutual fund holders include SBI Mutual Fund’s SBI Magnum Midcap Fund and SBI Contra Fund, Aditya Birla Sun Life Large Cap Fund, Nippon Mutual Funds’ Nippon Pharma Fund, Nippon Growth Fund, and Nippon India Small Cap Fund, along with Nippon India Multi Cap Fund. SBI Long Term Equity Fund and international funds like the Vanguard STAR Funds’ Total International Stock ETF and Vanguard FTSE Emerging Markets ETF also hold stakes. This investor base, ranging from the parent company to index giants, reinforces Sanofi India’s role as a significant holding in both thematic healthcare and diversified portfolios. 

The stock is also actively monitored using various technical and derivative indicators. Traders and investors track its futures and options to gauge market expectations around quarterly results and key regulatory decisions. Technical indicators such as the RSI, MACD, and MFI provide insight into short-term momentum and potential turning points in the Sanofi India stock price. While primarily for near-term trading, these tools help portfolio managers understand market sentiment and potential volatility around major events like product launches or policy announcements. 

Sanofi India’s beta values indicate that its stock price has historically been less volatile than the overall market. The long-term beta stands at 0.507. On a daily basis, the beta ranges from 0.340 over one month to 0.307 over three months, suggesting very low sensitivity to daily market swings. On a weekly basis, the beta is 0.774 over one year and 0.689 over two years, while a two-week range over two years shows a beta of 0.849. On a monthly basis over two years, the beta is 0.780. These figures consistently point to a stock that has exhibited lower volatility compared to the broader market, which can be attractive for investors seeking relative stability within a healthcare portfolio. 

Sanofi India Sectoral Relevance and Peer Positioning 

Sanofi India’s sector relevance stems from its strong portfolio of prescription drugs, vaccines, and consumer health products, establishing it as a key player in the Indian pharmaceutical ecosystem. Peer comparisons are often drawn with other multinational and large domestic pharma companies such as Abbott India, GlaxoSmithKline Pharmaceuticals, Pfizer, Sun Pharma, Divi’s Laboratories, and Cipla. The focus of these comparisons is on product portfolio strength, research capabilities, regulatory compliance, pricing power, and market share in key therapeutic segments rather than short-term stock movements. These benchmarks help investors assess operational scale, efficiency in marketing, and the company’s ability to navigate complex regulatory pathways. Institutional tracking of new product launches, volume growth in chronic therapies, and compliance with pricing regulations further highlights Sanofi India’s positioning within India’s broader pharmaceutical market. 

Sanofi India’s market cap has seen significant fluctuations over the years, reflecting its business cycles and market sentiment. Starting from ₹38.31 billion at the end of 2005, it grew steadily, crossing ₹100 billion by 2015. The market cap peaked at ₹191.56 billion in 2020 during the pandemic-driven healthcare rally, a growth of 18.56% from the previous year. However, it has since corrected. It declined by -5.11% to ₹181.78 billion in 2021, and by a steep -25.58% to ₹135.28 billion in 2022. A recovery in 2023 saw it jump 37.67% to ₹186.24 billion. This was followed by sharp declines: -24.06% in 2024 to ₹141.43 billion, -33.35% in 2025 to ₹94.26 billion, and a further -15.92% in 2026, bringing it to ₹79.26 billion. 

Sanofi India earnings has been uneven, showcasing the cyclical nature of the pharma business. Earnings stood at ₹2.63 billion in 2012, rising steadily to ₹7.48 billion by 2018, a 45.03% increase from the previous year. A dip followed in 2019 with a -19.81% decline to ₹6.00 billion. Earnings surged by 85.48% in 2021 to reach a high of ₹12.59 billion. However, they have since declined consistently: by -31.24% to ₹8.66 billion in 2022, -19.64% to ₹6.95 billion in 2023, and -37.79% to ₹4.32 billion in 2024. In 2025, the trailing twelve-month (TTM) earnings stood at ₹4.95 billion, showing a 14.51% increase from the previous year, though still well below the peaks of 2021. 

Sanofi India EPS provides a clear picture of its profitability on a per-share basis. In 2015, the EPS was ₹198.73. It then saw a decline of -8.38% to ₹182.08 in 2016. The following years witnessed growth, with EPS increasing 11.02% to ₹202.14 in 2017 and a further 9.2% to ₹220.75 in 2018. This peak in 2018 reflected strong profitability. However, after this period, the EPS trend turned negative. By 2025, the TTM EPS had declined to ₹162.66. This downward trend in EPS since 2018 is a critical factor explaining the recent pressure on the Sanofi India share price, as it indicates shrinking profitability despite the company’s strong brand portfolio. 

Sanofi India P/E ratio reflects how the market has valued its earnings over time. From 2015 to 2018, the P/E ratio expanded from 26.4 to 33.7, indicating that investors were willing to pay a premium for its earnings, likely due to growth expectations. A higher P/E of 33.7 at the end of 2018 meant the stock was relatively expensive compared to its earnings. Since then, the combination of a falling stock price and declining earnings has led to a contraction in its valuation multiple. The current P/E ratio (TTM) as of March 2026 stands at 19.4, a significant de-rating from its 2018 peak. This lower multiple suggests the market now has more modest expectations for the company’s future earnings growth. 

Summary 

Sanofi India Limited is a well-established entity in the domestic pharmaceutical sector with a strong portfolio of trusted brands. Its stock performance, as reflected in the Sanofi India share price, has faced significant headwinds in recent years due to competitive pressures and pricing challenges, leading to a marked underperformance against the broader sector and indices. While the company maintains strong parentage and institutional holding, its earnings and market cap have shown a declining trend. Its lower volatility, indicated by a beta below 1, offers a distinct characteristic for investors.